Synektik Sa · GPW:SNT

Synektik Sa — FY2023 Earnings Presentation

24 slides from Synektik Sa's earnings presentation, November 2024

  1. Slide 1: Investor Presentation Q4 2023 FY

    SYNEKTIK SA Investor Presentation Q4 2023 FY November 2024 Q4 FY 2023 Financial results | Investor presentation 1

  2. Slide 2: Synektik in snapshot

    Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 625m 146m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 1.47bn REVENUE FROM SALES, AJDUSTED EBITDA Enterprise value(2) PLN 1.41bn Q1-Q4 FY2023 Q1-Q4 FY2023 P/E(3) 13.9 EV/EBITDA(4) 9.8 Company profile  Integra

  3. Slide 3: Highlights of Q4 FY2023

    Highlights of Q4 FY2023 Sales of equipment and IT solutions – growing recurring revenue, expansion of the offer  PLN 129,1 million in revenue in Q4 FY2023,; increase in recurring revenue by 73%, to PLN 56.5 milion  Extension of the distribution agreement with Intuitive until at least the end of 20

  4. Slide 4: Financial performance in Q4 FY2023

    Financial performance in Q4 FY2023 Consolidated revenue (PLN million)  3% increase in total revenue from sales of equipment, IT solutions and the Q4 FY2023 141.8 provision of services (excluding intra-group transactions) +4% Q4 FY2022 136.7  28% increase in revenue of the radiopharmaceuticals segm

  5. Slide 5: Change in adjusted EBITDA

    Change in adjusted EBITDA PLN, million Q4 FY2022 Change in EBITDA by segments PLN, million (4.8) 0.0 31,7 31.7 26.9 26,9 +0.8 EBITDA R&D Other Adjusted Q4 FY2024 EBITDA +1.0 Q4 FY2024 2,7 +1.7 1,7 PLN +3.5m Medical device supply Radiopharmaceuticals General costs and IT solutions segment PLN, millio

  6. Slide 6: Financial performance in Q1-Q4 FY2023

    Financial performance in Q1-Q4 FY2023 Consolidated revenue (PLN million)  41% increase in total revenue from sales of equipment, IT solutions and the Q1-Q4 624.8 FY2023 provision of services (excluding intra-group transactions), to PLN 579.7m +40% FY2022 446.9  23% increase in revenue of the radio

  7. Slide 7: Group's adjusted EBITDA in FY 2020-2023

    Group’s adjusted EBITDA in FY 2020-2023 Adjusted EBITDA Summary 53.1 (PLNm)  EBITDA growth driven by: 35.2  increase in sales of equipment used in 29.8 32.4 31.7 25.5 24.9 therapy 13.3 10.9  growing scale of recurring sales in both 6.8 5.5 5.6 6.2 7.1 7.4 3.2 segments Q1 2020 Q1 2021 Q1 2022 Q1 2

  8. Slide 8: Group's recurring sales in FY 2020-2023

    Group’s recurring sales in FY 2020-2023 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) Drivers: 31.5  Dynamically increasing demand for consumable 30.2 parts and accessories for therapy equipment sold by the Synektik Group 29.5 Revenue from sales of radiopharmaceut

  9. Slide 9: Selected financial data

    Selected financial data PLN 000s Q4 FY 2023 Q4 FY 2022 Q1-Q4 FY 2023 Q1-Q4 FY 2022 Sales revenue  Surplus of cash over financial liabilities of PLN 61 141 819 135 688 624 797 446 872 - - million on 30 September 2024 EBIT 25 168 23 016 107 818 67 862 EBIT margin 18% 17% 17% 15%  Increase in trade p

  10. Slide 10: Medical equipment and IT solutions

    SYNEKTIK SA Medical equipment and IT solutions Q4 FY 2023 Financial results | Investor presentation 10

  11. Slide 11: Medical equipment and IT solutions: Key information

    Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas:  Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine 

  12. Slide 12: Medical equipment and IT solutions financial results

    Medical equipment and IT solutions Financial results (million PLN ) Dynamic revenue and profit growth 579.1  41% revenue growth year-over-year for the 12 months of the 2023 410.4 financial year, reaching 579.7 million PLN  45% normalized EBITDA growth in Q1-Q4 of the 2023 financial year, 144.0 98.

  13. Slide 13: Sales of medical equipment, orders for implementation

    Medical equipment and IT solutions Sales of medical equipment, orders for implementation Promising prospects for the coming quarters and active offers (in million PLN) 385.5 360.0  Secured orders worth 360 million PLN in 12 months of the 2023 financial year  The backlog value as of the end of Sept

  14. Slide 14: Da Vinci in Poland, Czech Republic and Slovakia

    Medical equipment and IT solutions Da Vinci in Poland, Czech Republic Da Vinci assisted surgical procedures in Poland, Czech Republic and Slovakia 7000 and Slovakia (number) 69 6000  Approximately 3.7 thousand surgeries with the assistance of Da Vinci in the fourth quarter of 2023 FY in Poland (up

  15. Slide 15: Da Vinci serviced by GK Synektik

    Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Słupsk Gdańsk Olsztyn 86 56 Szczecin Białystok Bydgoszcz Toruń Wieliszew Da Vinci systems serviced da Vinci systems Gorzów Wlkp. by GK Synektik in Poland* Poznań Warszawa Siedlce Zielona Góra Leszno Q3 2024 Nowa Sól Łódź Częs

  16. Slide 16: Strengthening cooperation with Intuitive - Baltic States

    Medical equipment and IT solutions Strengthening cooperation with Intuitive Baltic States – market potencial  Extension of the cooperation agreement with Intuitive until December 31, 2029: Lithuania, Bulgaria Latvia, Estonia  Medium-term plans to add new systems from the da Vinci family to the Syn

  17. Slide 17: A strong start of 2024 FY

    Medical equipment and IT solutions A strong start of 2024 FY  In the first quarter of the 2024 fiscal year, the following agreements were signed:  Five contracts for the delivery of da Vinci systems, with a total value of PLN 74.7 million.  Two significant contracts for the supply of consumable i

  18. Slide 18: Radiopharmaceuticals

    SYNEKTIK SA Radiopharmaceuticals Q4 FY 2023 Financial results | Investor presentation 18

  19. Slide 19: Radiopharmaceuticals: Key information

    Radiopharmaceuticals Key information  Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 50+ Number of 3 Production sites together employees with R&D Centre  Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac

  20. Slide 20: Radiopharmaceuticals: Growing revenues and margins

    Radiopharmaceuticals Growing revenues and margins Financial results (million PLN )  23% increase in sales (year-over-year) in the 12 months of 2023, up to 45.1 45.1 million PLN 36.5  25%, increase in sales of basic markers, up to 23.4 million PLN, resulting 16.3 from the increase in the number of

  21. Slide 21: Cardiotracer

    SYNEKTIK SA Cardiotracer Q4 FY 2023 Financial results | Investor presentation 21

  22. Slide 22: Cardiotracer

    Cardiotracer Continuation of the process of publishing the results of Phase I and II clinical trials: EANM - Hamburg, 10/2024 Prof. Juhani Knuuti, Turku University Hospital, Finland Prof. Mirosław Dziuk, WIM, Warsaw CONCLUSIONS: CONCLUSIONS:  Based on the safety profile of the cardiac marker SYN2,

  23. Slide 23: Q&A Session

    SYNEKTIK SA Q&A SESSION Q4 FY 2023 Financial results | Investor presentation 23

  24. Slide 24: Thank You!

    Cezary Kozanecki Thank You! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl

Synektik — FY2023 Earnings Presentation on 6ix